Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML

A Clinical Study to Investigate the Safety and Efficacy of CT0890B in Patients with Relapsed/Refractory Acute Myeloid Leukemia.

Trial Details

NCT ID
NCT07617285
Phase
PHASE1
Sponsor
Peking University People's Hospital
Status
RECRUITING
Cancer Type
Acute Myeloid (AML) Leukemia
Interventions
  • CAR-T cells chimeric antigen receptor T cells
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Age 18-70 years (inclusive), male or female.
  • Relapsed or refractory acute myeloid leukemia (R/R AML) diagnosed according to the 2022 World Health Organization classification or ELN criteria, w…
  • Bone marrow blasts ≥5% by morphology.
  • Estimated life expectancy \>12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Myeloid (AML) Leukemia Trials on Trialify →